Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
PR Newswire•26/10/2026•07:00 ET
0
Key Highlights
- ➤Compugen (CGEN) will release Q3 2026 results November 9 before U.S. markets open
- ➤Management will host an 8:30 AM ET conference call and corporate update
- ➤Rilvegostomig is being evaluated in multiple Phase 3, Phase 2 and Phase 1 trials
- ➤GS-0321 is licensed to Gilead and undergoing a Phase 1 trial
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026 PR Newswire
HOLON, Israel, Oct. 26, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, today announced that the Company will release its third quarter 2026 financial results on Monday, November 9, 2026, before the U.S. financial markets open. That same day, management will host a conference call to review the results and provide a corporate update at 8:30 AM ET.
Get started
Create a free account to read the full story.